Zymeworks Inc. — Form 8-K
Filed October 23, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Zymeworks entered into an exclusive global license and collaboration agreement with Roche for ZW209, a trispecific T cell engager targeting DLL3. Zymeworks receives $55 million upfront, $40 million upon Phase 1b initiation, and up to $718 million in development/commercial/sales milestones, plus tiered high-single-digit to mid-teen royalties on global net sales. Roche funds Phase 1a trial and holds exclusive global development and commercialization rights; deal closes subject to HSR Act clearance.
Why this rating
Major out-licensing deal worth $95M cash near-term (14.6% of $649.5M market cap) plus substantial contingent value. Validates ZW209, de-risks development via Roche partnership, aligns with asset-generation strategy, but transfers upside control.
Price action (we called it positive)
at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 23, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.